Goodvibes Photo/iStock via Getty Images Asian equity markets advanced on Monday, powered by a sweeping rally in technology shares as investor enthusiasm for artificial intelligence eclipsed lingering uncertainties surrounding a potential U.S.-Iran peace agreement. Gold prices steadied above $4,500 an ounce. WTI crude futures climbed toward $90 per barrel. The benchmark KOSPI climbed more than 3% t...
Goodvibes Photo/iStock via Getty Images Asian equity markets advanced on Monday, powered by a sweeping rally in technology shares as investor enthusiasm for artificial intelligence eclipsed lingering uncertainties surrounding a potential U.S.-Iran peace agreement. Gold prices steadied above $4,500 an ounce. WTI crude futures climbed toward $90 per barrel. The benchmark KOSPI climbed more than 3% to around 8,750. Japan's ( NKY:IND ) rose 0.78% to around 66,900, reaching a fresh record high. The Japanese yen traded around 159.5 per dollar, remaining under pressure and hovering near the closely watched 160 level. The S&P Global Japan Manufacturing PMI for May 2026 was confirmed at 54.5, matching the preliminary estimate, lower than April's 55.1 but still indicating growth, although at a slower pace. Meanwhile, Japan’s capital spending was unchanged in the first quarter compared with a year earlier, pointing to a slowdown in corporate investment. Market participants are now awaiting remarks from BOJ Governor Kazuo Ueda later this week for further insight into the central bank’s policy outlook. China's ( SHCOMP ) rose 0.22% to 4,053, its lowest level in over a month, while the Shenzhen Component rose 0.3% to 15,622 , and the offshore yuan edged lower to around 6.76 per dollar, retreating from a more than three-year high reached in the previous session. The RatingDog China Manufacturing PMI eased to 51.8 from April’s over five-year high of 52.2. The government's official NBS Manufacturing PMI edged down to 50.0 from 50.3 in April, perfectly matching market forecasts. The official NBS Non-Manufacturing PMI jumped to 50.1 from 49.4 in April. China’s NBS Composite PMI Output Index ticked up to 50.5 from 50.1 in April. Hong Kong ( HSI ) rose 0.94% to 25,357, kicking off the new month on a positive note. India ( SENSEX ) rose 0.02% to 74,982, rebounding from losses in the last three straight sessions. The Indian rupee strengthened to around 94.7 per dollar. India’s HSBC Manufa...
(RTTNews) - SoftBank Group Corp. (9984.T, SFTBY) announced that its joint venture with a French AI and high-performance computing infrastructure company, Sesterce Group, has been selected to develop and operate a 1 GW artificial intelligence data center campus in Bosquel, France.
(RTTNews) - SoftBank Group Corp. (9984.T, SFTBY) announced that its joint venture with a French AI and high-performance computing infrastructure company, Sesterce Group, has been selected to develop and operate a 1 GW artificial intelligence data center campus in Bosquel, France.
UCB and Biogen ( BIIB ) on Monday said that their investigational drug dapirolizumab pegol met the primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a BICLA response at week 48 compared to 35% on placebo (p=0.011). The drug is an Fc-free CD40L inhibitor tested in moderate-to-severe active systemic lupus erythematosus (SLE). BICLA is a composite en...
UCB and Biogen ( BIIB ) on Monday said that their investigational drug dapirolizumab pegol met the primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a BICLA response at week 48 compared to 35% on placebo (p=0.011). The drug is an Fc-free CD40L inhibitor tested in moderate-to-severe active systemic lupus erythematosus (SLE). BICLA is a composite endpoint measuring clinically relevant improvement of disease activity across all affected organ systems with no worsening in other lupus domains; a higher BICLA response rate reflects a treatment response and is associated with clinical benefit. Because the first key secondary endpoint was not met (BICLA response at week 24), subsequent outcomes were not controlled for multiplicity. Results in favor of DZP plus SOC were observed across multiple outcomes, including severe BILAG flares, SRI-4, SLEDAI-2K, skin- and joint-related outcomes, and the serological markers anti-dsDNA antibodies and complement C3 and C4, the companies said. Serious adverse events were less frequent with dapirolizumab pegol at 10% versus 14.8% on placebo. The confirmatory Phase 3 PHOENYCS FLY trial is currently recruiting patients. More on Biogen Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade) Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity Biogen Inc. (BIIB) Presents at Bank of America Global Healthcare Conference 2026 Transcript Biogen faces Italian antitrust probe over rivalry with Sandoz for MS drugs Biogen, Denali to drop Parkinson’s therapy after mid-stage trial setback